WuXi Biologics (Cayman) Inc
HKEX:2269
EV/OCF
Enterprise Value to OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
Market Cap | EV/OCF | ||||
---|---|---|---|---|---|
CN |
WuXi Biologics (Cayman) Inc
HKEX:2269
|
55.4B HKD | 9.5 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
225.3B USD | 27.9 | ||
US |
Danaher Corp
NYSE:DHR
|
197.4B USD | 29.7 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45B USD | 23.4 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.6B USD | 24.7 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.4T KRW | 32.8 | ||
CH |
Lonza Group AG
SIX:LONN
|
36.6B CHF | 27.1 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 34.2 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.3B USD | 22.3 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
24.6B USD | 31.8 | ||
US |
Waters Corp
NYSE:WAT
|
20.9B USD | 33.7 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.